hit counter
Akebia Therapeutics, Inc. (AKBA) Stock News Sentiment & Price - Sentifly
AKBA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Akebia Therapeutics, Inc. (AKBA)

USA
Biotechnology
NASDAQ
AKBA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AKBA Latest news
Seeking Alpha
Neutral
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2021 Results - Earnings Call Transcript
2021-11-09 15:38

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
2021-11-04 10:42

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -6.25% and -2.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire
Neutral
Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
2021-11-04 08:05

CAMBRIDGE, Mass., Nov. 4, 2021 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.

PRNewsWire
Neutral
Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors
2021-11-01 08:00

CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors.

Zacks Investment Research
Negative
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2021-10-28 16:48

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire
Neutral
Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones
2021-10-26 08:00

CAMBRIDGE, Mass., Oct. 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2021, on Thursday, November 4, 2021 before the opening of the financial markets.

PRNewsWire
Neutral
Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021
2021-10-18 08:00

CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 – November 7, 2021.

InvestorPlace
Positive
7 Small-Cap Stocks to Buy From the Beat-Up Bargain Bin
2021-10-11 14:04

Unwilling to wait for catalysts, some investors threw these small-cap stocks into the garbage bin. But that doesn't mean they won't succeed.

PRNewsWire
Neutral
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-01 16:05

CAMBRIDGE, Mass., Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 89,000 shares of Akebia's common stock on August 31, 2021, as inducements material to each such employee's entering into employment with Akebia.

PRNewsWire
Neutral
Akebia Therapeutics Announces September 2021 Investor Conference Schedule
2021-09-01 08:00

CAMBRIDGE, Mass. , Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

Loading more news...